Novartis India launches Pluvicto for prostate cancer treatment
Novartis India has launched Pluvicto, a new radioligand therapy for patients with PSMA-positive metastatic prostate cancer. This treatment aims to provide a more targeted approach to care as prostate cancer rates continue to rise among urban men in India.
Why it matters
It introduces advanced precision oncology to the Indian market, potentially improving outcomes for a rapidly growing patient demographic.
For better cancer care in India, Novartis India has announced the launch of Pluvicto (lutetium (177Lu) vipivotide tetraxetan), the country’s first regulatory authority approved radioligand therapy for eligible patients with Prostate-Specific Membrane Antigen (PSMA)-positive prostate cancer.
The article reports on a corporate product launch using standard industry terminology without inflammatory or promotional language.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in